Skip Ribbon Commands
Skip to main content
Home Administrative Billing & Reimbursement BlueCard® Health and Wellness Medical PEAR portal Pharmacy Products Quality Management

​Changes to medical policy on patisiran (Onpattro®) and vutrisiran (Amvuttra™)

March 14, 2023

​Effective June 12, 2023, Independence Blue Cross and Independence Administrators will update their medical policy on patisiran (Onpattro®) and vutrisiran (Amvuttra™) for both Commercial and Medicare Advantage members.

This policy will be updated to include a new drug, vutrisiran (Amvuttra™), which was approved by the U.S. Food and Drug Administration in June 2022 and has coverage criteria that needs to be met. The updated policy will also include more coverage changes for patisiran (Onpattro®), including the restriction of combination therapies with drugs that act similarly.

For more information, please view the following notifications that were published on March 14, 2023:

This content was prepared for the Provider News Center and may not be reproduced in any way without the express written permission of Independence Blue Cross. Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association.
Connect with us     Facebook     Twitter     Flickr     YouTube     Walk the Talk    Independence Pinterest    Independence LinkedIn    Independence Instagram Site Map        Anti-Fraud        Privacy Policy        Legal        Disclaimer
© 2023 Independence Blue Cross.
Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association, serving the health insurance needs of Philadelphia and southeastern Pennsylvania.